Abstracts tagged "Biomarkers"

Abstract Number: 1441 • 2017 ACR/ARHP Annual Meeting
Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Shinya Kawashiri^1,2,3, Ayako Nishino^3,4, Nobutaka Eiraku³, Tamami Yoshitama³, Naoki Matsuoka³, Toshiyuki Aramaki³, Yukitaka Ueki³, Akitomo Okada³, Hiroaki Hamada³, Shuji Nagano³, Keita Fujikawa³ and Atsushi Kawakami^1,3, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Departments of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁴Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: We have been prospectively investigating therapeutic efficacy of biologic or targeted synthetic DMARDs in patients with rheumatoid arthritis (RA) by ultrasound (US) in Kyushu…
Abstract Number: 2198 • 2017 ACR/ARHP Annual Meeting
Combinatorial Peripheral Blood Inflammatory and MRI-Based Biomarkers Predict Radiographic Joint Space Narrowing in Knee OA
Svetlana Krasnokutsky Samuels¹, Hua Zhou², Mukundan Attur¹, Jonathan Samuels¹, Gregory Chang³, Jenny Bencardino⁴, Sisi Ma², Leon Rybak³ and Steven B. Abramson⁵, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Bioinformatics, New York University, New York, NY, ³Department of Radiology, NYU Langone Medical Center, New York, NY, ⁴Radiology, NYU Langone Medical Center, New York, NY, ⁵Dept of Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: Inflammation contributes to OA disease pathogenesis. Subsets of knee OA patients with peripheral blood leukocyte (PBL) detected inflammatory gene expression profiles exhibit more rapid…
Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Paul Studenic¹, Stephan Blüml¹, Holger Bang², Daniela Sieghart¹, Daniel Aletaha¹, Helmuth Haslacher³, Josef S. Smolen^1,4 and Günter Steiner¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, ⁴Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
Abstract Number: 138 • 2017 ACR/ARHP Annual Meeting
Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity
Fenglong Xie¹, Lang Chen², Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The ACC/AHA recommends preventive strategies for patients with a high predicted risk of atherosclerotic cardiovascular disease (CVD). RA patients are at higher risk for…
Abstract Number: 679 • 2017 ACR/ARHP Annual Meeting
Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE
Katherine Dutton¹, Antonios Psarras², Md Yuzaiful Md Yusof², Paul Emery³, Yasser M El-Sherbiny⁴ and Edward M Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom
Background/Purpose: Type I interferon (IFN-I) has a crucial role in the pathogenesis and activity of Systemic Lupus Erythematosis (SLE). IFN-I targeted therapies are currently in…
Abstract Number: 971 • 2017 ACR/ARHP Annual Meeting
Synovial Fibroblast CD318 Expression Mediates T Cell Adhesion and Migration in Rheumatoid Arthritis
Ray A. Ohara¹, Stephanie M. Rasmussen¹, W. Alexander Stinson¹, Huadong Cui¹, Yuxuan Du¹, Daniel P. Weber¹, M. Asif Amin¹, Phillip L. Campbell², Nora Singer³, Feng Lin⁴, David A. Fox¹ and Jeffrey H. Ruth⁵, ¹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ²Ann Arbor, MI, ³Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH, Cleveland, OH, ⁴Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, Cleveland, OH, ⁵Internal Medicine, Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI
Background/Purpose: CD6 is an important marker and regulator of T cells and interacts with its known ligand, CD166. Our group has previously shown that interferon…
Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Arata Nakajima¹, Masato Sonobe¹, Shinji Taniguchi¹ and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ²Toho University Sakura Medical Center, Sakura-city, Chiba, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 2207 • 2017 ACR/ARHP Annual Meeting
Urine CTX-II, CTX-I, Osteocalcin, and Radiographic Severity of Multiple OA Knee Joints: Does CTX-II Originate from Bone or Cartilage?
Asger R. Bihlet¹, Inger Byrjalsen², Anne C. Bay-Jensen³, Jeppe Andersen⁴, Claus Christiansen¹, Bente J. Riis¹ and Morten Asser Karsdal³, ¹Nordic Bioscience, Clinical Development, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁴Clinical Development, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Excessive cartilage degradation is a known characteristic of osteoarthritis (OA), and several methods of quantification of cartilage degradation exist. Biomarkers such as urinary C-telopeptide…
Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting
CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
Vikas Gupta¹, Shobhita Katiyar², Ankita Singh², Ramnath Misra¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…
Abstract Number: 173 • 2017 ACR/ARHP Annual Meeting
Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Jessica Turnier¹, Bruce Aronow², Kenneth Greis³, Michael Bennett⁴, Wendy Haffey³, Sherry Thornton⁵, Gaurav Gulati⁶, Michael Wagner⁷, David Witte⁸, Prasad Devarajan⁹ and Hermine I. Brunner¹⁰, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Non-invasive biomarkers of lupus nephritis (LN) damage are needed to guide treatment decisions and determine risk for kidney failure. Urinary proteomics has advanced as…
Abstract Number: 680 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)
Cristina Arriens¹, Sonali Narain², Amit Saxena³, Christopher E. Collins⁴, Daniel J. Wallace⁵, Elena Massarotti⁶, John Conklin⁷, Roberta Alexander⁷, Kenneth C. Kalunian⁸, Chaim Putterman⁹, Rosalind Ramsey-Goldman¹⁰, Jill P. Buyon¹¹, Anca Askanase¹², Richard Furie², Susan Manzi¹³, Joseph Ahearn¹⁴, Arthur Weinstein¹⁵ and Thierry Dervieux⁷, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Northwell Health, Great Neck, NY, ³Rheumatology, NYU Langone Medical Center, New York, NY, ⁴Rheumatology, MedStar Washington Hospital Center, Washington, DC, ⁵Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Exagen Diagnostics, Inc., Vista, CA, ⁸Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰FSM, Northwestern University, Chicago, IL, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²Rheumatology, Columbia University, New York, NY, ¹³Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁵Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: We sought to evaluate the relationships between low complement C3 and C4 proteins, abnormal complement activation (cell-bound complement activation products [CB-CAPs]), and a Lupus…
Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting
Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics
Jun Ishizaki¹, Ayako Takemori², Koichiro Suemori¹, Takuya Matsumoto¹, Yoko Akita¹, Masaki Yasukawa¹, Nobuaki Takemori² and Hitoshi Hasegawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan
Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Mireia Moreno¹, Caridad Pontes², Ferran Torres³, Agusti Sellas-Fernandez⁴, Miriam Almirall⁵, Juan Carlos Torre-Alonso⁶, Teresa Clavaguera⁷, Carlos Rodriguez-Lozano⁸, Luis Francisco Linares⁹, Ana Urruticoechea-Arana¹⁰, Eduardo Collantes-Estevez¹¹, Rosa Morla¹², Delia Reina¹³, Eduardo Cuende¹⁴, Pedro Zarco¹⁵, Cruz Fernandez-Espartero¹⁶, Rosario García-Vicuña¹⁷, Jesus Sanz¹⁸, Xavier Juanola¹⁹, Antoni Vallano²⁰, Francisco J Blanco²¹, Raimon Sanmarti²², Gonzalo Calvo²³, Cristina Avendaño²⁴, Eugenio De Miguel²⁵, Roser Vives²⁶, Raul Veroz Gonzalez²⁷, Carlos Alberto Montilla-Morales²⁸ and Jordi Gratacos-Masmitja²⁹, ¹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ²Clinic Pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁵Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶H Monte Naranco, Oviedo, Spain, ⁷Rheumatology. Palamós Hospital, Rheumatologist, Catalonia, Spain, ⁸Rheumatology, Hospital Universitario Dr. Negrin, Gran Canaria, Spain, ⁹Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁰Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹¹Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, ¹²Rambla Vella, 14, Hospital La Tecla, Tarragona, Spain, ¹³Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹⁵H Fundación Alcorcón, Alcorcón, Spain, ¹⁶Rheumatology, Hospital de Mostoles, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁰Clinic pharmacology, Hospital Universitari Bellvitge, Barcelona, Spain, ²¹Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²²Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ²³Clinic pharmacology, Hospital Clinic Barcelona, Barcelona, Spain, ²⁴Clinic pharmacology, Hospital Puerta de Hierro, Madrid, Spain, ²⁵Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²⁶Clinic pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ²⁷Hospital de Mérida, Mérida, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…
Abstract Number: 2322 • 2017 ACR/ARHP Annual Meeting
Quantitative Proteomics Comparison of Children with Inactive and Active Uveitis
Sheila Angeles-Han¹, Duc Duong², Steven Yeh³, Purnima Patel⁴, Virginia Miraldi Utz⁵, Kirsten Jenkins⁶, Danielle Lowe⁷, Sampath Prahalad⁸ and Gary Holland⁹, ¹Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ²Emory University, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ⁶Children's Healthcare of Atlanta, Atlanta, GA, ⁷Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁹Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with chronic non-infectious uveitis are at high risk for sight-threatening complications and vision loss. No biomarker predicts uveitis development or treatment response. Aqueous…
Abstract Number: 2875 • 2017 ACR/ARHP Annual Meeting
Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets
Judith A. James¹, Joel M. Guthridge², Hua Chen³, Rufei Lu³, Rebecka L. Bourn³, Alan N. Baer⁴, Ghaith Noaiseh⁵, Anne Parke⁶, Andreea Coca⁷, Tammy Utset⁸, Mark C. Genovese⁹, Teresa Aberle³, Daniel J. Wallace¹⁰, Karen Boyle¹¹, Lynette Keyes-Elstein¹², Nathalie Franchimont¹³, Eugene St. Clair¹⁴, Virginia Pascual¹⁵, Paul J. Utz¹⁶ and Kathy L. Sivils², ¹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶University of Connecticut, Farmington, CT, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Chicago, Chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA, ¹⁰UCLA, Beverly Hills, CA, ¹¹Rho Federal Systems, Inc, Chapel Hill, NC, ¹²Rho Federal Systems, Inc., Chapel Hill, NC, ¹³Biogen, Cambridge, MA, ¹⁴Department of Medicine, Duke University Medical Center, Durham, NC, ¹⁵Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ¹⁶Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Immunologic heterogeneity in primary Sjogren’s syndrome (pSS) poses a challenge when selecting a therapeutic for a given patients or when assembling patient cohorts for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.